Author:
Deres Karl,Schröder Claus H.,Paessens Arnold,Goldmann Siegfried,Hacker Hans Jörg,Weber Olaf,Krämer Thomas,Niewöhner Ulrich,Pleiss Ulrich,Stoltefuss Jürgen,Graef Erwin,Koletzki Diana,Masantschek Ralf N. A.,Reimann Anja,Jaeger Rainer,Groß Rainer,Beckermann Bernhard,Schlemmer Karl-Heinz,Haebich Dieter,Rübsamen-Waigmann Helga
Abstract
Chronic hepatitis B virus (HBV) infection is a major cause of liver disease. Only interferon-α and the nucleosidic inhibitors of the viral polymerase, 3TC and adefovir, are approved for therapy. However, these therapies are limited by the side effects of interferon and the substantial resistance of the virus to nucleosidic inhibitors. Potent new antiviral compounds suitable for monotherapy or combination therapy are highly desired. We describe non-nucleosidic inhibitors of HBV nucleocapsid maturation that possess in vitro and in vivo antiviral activity. These inhibitors have potential for future therapeutic regimens to combat chronic HBV infection.
Publisher
American Association for the Advancement of Science (AAAS)